<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03450772</url>
  </required_header>
  <id_info>
    <org_study_id>PANC3016</org_study_id>
    <nct_id>NCT03450772</nct_id>
  </id_info>
  <brief_title>Equivalence Study to Compare Two Strengths of Creon in China</brief_title>
  <acronym>CREON</acronym>
  <official_title>Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be an open-label, randomized, multicenter, cross-over study in 60 subjects with PEI&#xD;
      delivering data of 60 subjects for Pancreatin Enteric-Coated Capsules 25000 and of 60&#xD;
      subjects for Pancreatin Enteric-Coated Capsules 10000. The study will be conducted in up to&#xD;
      10 sites in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coefficient of fat absorption</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fat intake - fat excretion/fat intake x 100</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stool weight</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptomatology</measure>
    <time_frame>5 days and 24 weeks</time_frame>
    <description>stool frequency, stool consistency, abdominal pain, flatulence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's acceptance of treatment and preference</measure>
    <time_frame>5 days and 24 weeks</time_frame>
    <description>Subject's acceptance of treatment will be judged based on the following scale: very good, good, moderate and unsatisfactory.&#xD;
Which treatment did you prefer? No difference between treatment 1 and treatment 2 Treatment 1 is better than treatment 2 Treatment 2 is better than treatment 1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Insufficiency</condition>
  <arm_group>
    <arm_group_label>Creon® 25000 then Creon® 10000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pancreatic enzyme</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Creon® 10000 then Creon® 25000</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pancreatic enzyme</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon® 25000</intervention_name>
    <description>Experimental drug</description>
    <arm_group_label>Creon® 25000 then Creon® 10000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creon® 10000</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Creon® 10000 then Creon® 25000</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Subjects ≥ 18 years&#xD;
&#xD;
          -  A) Chronic pancreatitis must be documented in the medical file by at least one of the&#xD;
             following methods:&#xD;
&#xD;
               -  Imaging techniques (ultrasound, CT, MRI, or endoscopic ultrasound)&#xD;
&#xD;
               -  ERCP (endoscopic retrograde cholangiopancreatography)&#xD;
&#xD;
               -  Plain film of the abdomen with pancreatic calcification or&#xD;
&#xD;
          -  B) Partial or total pancreatectomy ≥ 30 days prior to enrollment and without current&#xD;
             postsurgery complications&#xD;
&#xD;
          -  PEI proven by human fecal elastase ≤ 100 µg/g stool (during the screening period)&#xD;
&#xD;
          -  Subjects without Creon (Pancreatin Enteric Coated Minimicrospheres) intake in the past&#xD;
             three months&#xD;
&#xD;
          -  Females of child-bearing potential should agree to continue using a medically&#xD;
             acceptable method of birth control throughout the study and for 30 days immediately&#xD;
             after the last dose of study drug. Medically acceptable methods of birth control&#xD;
             include bilateral tubal ligation or the use of either a contraceptive implant, a&#xD;
             contraceptive injection (e.g. Depo-Provera™), an intrauterine device, or an oral&#xD;
             contraceptive taken within the past three months where the subject agrees to continue&#xD;
             using during the study or to adopt another birth control method, or a double-barrier&#xD;
             method which consists of a combination of any two of the following: diaphragm,&#xD;
             cervical cap, condom, or spermicide&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of fibrosing colonopathy&#xD;
&#xD;
          -  Solid organ transplant&#xD;
&#xD;
          -  Surgery affecting the stomach or bowel, except pancreatectomy or appendectomy&#xD;
&#xD;
          -  Surgery affecting the stomach or bowel, except pancreatectomy or appendectomy&#xD;
&#xD;
          -  Subjects with recurrent malignant tumors of any kind&#xD;
&#xD;
          -  Use of an immunosuppressive drug or chemotherapy&#xD;
&#xD;
          -  Acute phase of pancreatitis&#xD;
&#xD;
          -  Acute phase of pancreatitis&#xD;
&#xD;
          -  Subjects who are not able or willing to ingest 90g fat/day (± 10 g fat/day) during the&#xD;
             cross-over periods or are not willing to collect complete stools during the&#xD;
             demarcation period.&#xD;
&#xD;
          -  Subjects in an instable condition after pancreatic surgery (Karnofsky index &lt; 70)&#xD;
&#xD;
          -  Known infection with HIV&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Current excessive alcohol intake or drug abuse&#xD;
&#xD;
          -  Investigational drug intake within prior 30 days&#xD;
&#xD;
          -  Known allergy against pancreatin of porcine origin or to any of the excipients of&#xD;
             Pancreatin Enteric-Coated Capsules&#xD;
&#xD;
          -  Suspected non-compliance or non-cooperation&#xD;
&#xD;
          -  Celiac disease, Crohn´s disease&#xD;
&#xD;
          -  Ileus or acute abdomen in the medical history&#xD;
&#xD;
          -  Mental disability or any other lack of fitness, in the investigator's opinion, to&#xD;
             preclude subject's participation in or to complete the study&#xD;
&#xD;
          -  Any acute or chronic disease (i.e infectious diseases) which may limit the&#xD;
             hospitalization, dietary adherence or stool collection or completion of the study&#xD;
             procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suntje Sander, PhD</last_name>
    <phone>+495116750</phone>
    <phone_ext>3254</phone_ext>
    <email>suntje.sander@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhaoshen, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

